“点击蓝字 关注我们恒瑞创新药氟唑帕利胶囊前列腺癌新适应症上市申请获受理PPS近日,恒瑞医药收到国家药品监督管理局下发的《受理通知书》,公司自主研发的1类新药氟唑帕利胶囊(艾瑞颐®)的药品上市许可申请获受理,适应症为:该品联合阿比特龙和泼尼松或泼尼松龙用于DNA修复基因缺陷阳性(DRD+)的转移性去势抵抗性前列腺癌的一线治疗。关于SHR3162-III-305研究此次申报上市,是基于一项在转移性...
Source Link“点击蓝字 关注我们恒瑞创新药氟唑帕利胶囊前列腺癌新适应症上市申请获受理PPS近日,恒瑞医药收到国家药品监督管理局下发的《受理通知书》,公司自主研发的1类新药氟唑帕利胶囊(艾瑞颐®)的药品上市许可申请获受理,适应症为:该品联合阿比特龙和泼尼松或泼尼松龙用于DNA修复基因缺陷阳性(DRD+)的转移性去势抵抗性前列腺癌的一线治疗。关于SHR3162-III-305研究此次申报上市,是基于一项在转移性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.